Skip to content

NICE Decision Support Unit

  • Home
  • Contact
    • Staff and Network
  • Training
    • Online training
  • Appraisal Specific
    • Alzheimer’s disease
    • Age-related macular degeneration
    • Ankylosing spondylitis
    • Breast cancer – lapatinib
    • Colorectal cancer – cetuximab
    • Crohn’s disease
    • Diabetes – dapagliflozin
    • Diabetes – liraglutide
    • Lung cancer – erlotinib
    • Lupus – belimumab
    • Macular oedema – bevacizumab
    • Myelodysplastic syndromes
    • Osteoporosis
    • Prostate cancer – degarelix
    • Renal cell carcinoma
    • Rheumatoid arthritis
    • Ribociclib
  • Methods Development
    • Accelerated Access Collaborative:
    • CHTE2020 Qualitative Evidence
    • CHTE2020 Sources and Synthesis of Evidence
    • The use of cost minimisation analysis for the appraisal of health technologies
    • Crossover and survival
    • EMU – Stata command
    • End of Life
    • EQ5D
    • EQ-5D-5L
    • Future unrelated costs
    • Managed Entry Agreements (MEA)
    • Mapping of EQ-5D
    • Mapping for Technology Appraisals
    • MCDA
    • Measuring and valuing health-related quality of life when sufficient data is not directly observed
    • Modelling carer health-related quality of life
    • NICE Methods Guide updates
    • Not cost-effective at £0
    • PFS-OS
    • QALY weighting
    • Quality assurance – models
    • Quality of Life in Cancer
    • Real World Data
    • Regression methods
    • Review of the STA process
    • Utility Values in Children
    • Value based pricing/assessment
    • Value of Information
    • Value of Innovation
  • Technical Support Documents
    • TSDs completed or currently in progress
    • TSD Summaries
    • Evidence Synthesis TSD series
    • Flexible Methods for Survival Analysis TSD
    • Multivariate meta-analysis TSD
    • Observational data TSD
    • Partitioned survival analysis TSD
    • Patient-level simulation TSD
    • Population-adjusted indirect comparisons (MAIC and STC)
    • Reviewing model parameters TSD
    • Survival analysis TSD
    • Treatment switching TSD
    • Utilities TSD series
  • Publications

Breast cancer – lapatinib


LAPATINIB

NICE Appraisal

Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) (in progress)

DSU Reports

Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer): post appeal (September 2009)

Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer)  (September 2008)

Tweets by @NICE_DSU

Subscribe for new reports

Check your inbox or spam folder to confirm your subscription.

  • Home
  • Contact
    • Staff and Network
  • Training
    • Online training
  • Appraisal Specific
    • Alzheimer’s disease
    • Age-related macular degeneration
    • Ankylosing spondylitis
    • Breast cancer – lapatinib
    • Colorectal cancer – cetuximab
    • Crohn’s disease
    • Diabetes – dapagliflozin
    • Diabetes – liraglutide
    • Lung cancer – erlotinib
    • Lupus – belimumab
    • Macular oedema – bevacizumab
    • Myelodysplastic syndromes
    • Osteoporosis
    • Prostate cancer – degarelix
    • Renal cell carcinoma
    • Rheumatoid arthritis
    • Ribociclib
  • Methods Development
    • Accelerated Access Collaborative:
    • CHTE2020 Qualitative Evidence
    • CHTE2020 Sources and Synthesis of Evidence
    • The use of cost minimisation analysis for the appraisal of health technologies
    • Crossover and survival
    • EMU – Stata command
    • End of Life
    • EQ5D
    • EQ-5D-5L
    • Future unrelated costs
    • Managed Entry Agreements (MEA)
    • Mapping of EQ-5D
    • Mapping for Technology Appraisals
    • MCDA
    • Measuring and valuing health-related quality of life when sufficient data is not directly observed
    • Modelling carer health-related quality of life
    • NICE Methods Guide updates
    • Not cost-effective at £0
    • PFS-OS
    • QALY weighting
    • Quality assurance – models
    • Quality of Life in Cancer
    • Real World Data
    • Regression methods
    • Review of the STA process
    • Utility Values in Children
    • Value based pricing/assessment
    • Value of Information
    • Value of Innovation
  • Technical Support Documents
    • TSDs completed or currently in progress
    • TSD Summaries
    • Evidence Synthesis TSD series
    • Flexible Methods for Survival Analysis TSD
    • Multivariate meta-analysis TSD
    • Observational data TSD
    • Partitioned survival analysis TSD
    • Patient-level simulation TSD
    • Population-adjusted indirect comparisons (MAIC and STC)
    • Reviewing model parameters TSD
    • Survival analysis TSD
    • Treatment switching TSD
    • Utilities TSD series
  • Publications
NICE Decision Support Unit Proudly powered by WordPress